Chronos Archive seal

Review checklist: Jacqueline du Pré (HR-ML039)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the application of the 2017 McDonald criteria and the 2024 revision, the decision to test aquaporin-4 but not MOG antibody, intravenous rather than oral methylprednisolone for the relapse, the choice of ocrelizumab over natalizumab (JCV antibody positive) and ofatumumab, the timing of vaccines before B-cell depletion, and the management of a pseudo-relapse with cystitis.
provenance reviewnot_startedShe died in 1987; the recent-death rule does not apply, but her husband and siblings are living or recently living public people and none of them is named; contested family accounts are not used. Claims rest on a 2018 peer-reviewed review, an essay by two Mayo Clinic physicians, Wikipedia and Women in World History; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail, and later disputed claims about it are not used. No relative is named or given a role in the modern episode.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule and living relatives. She died in 1987, before the rule’s threshold, so it does not apply. Her husband and her siblings, however, are living or recently living public people. None of them is named anywhere in the record; her husband appears only as “her husband, a pianist and conductor,” in the documented history of her marriage (CLM-0004) and in the modern household, with no role, statement or health fact. The family memoir and the claims drawn from it, an account attributed to her husband of how her first symptoms began, and later disputed claims about her death are not used at all.
  2. Sources not used. The Jacqueline du Pré Charitable Trust, the MS Society UK and the Royal Academy of Music pages on her were not found; the New York Times obituary could not be fetched; the Guardian obituary was not found; Britannica and the Jewish Women’s Archive could not be fetched (403). Elizabeth Wilson’s biography was not read, and no reliable quotation of its medical account was found; it is not cited. The 2018 review cites Carol Easton’s biography, which was not read.
  3. Name. The display name is Jacqueline du Pré. Splitting at the last space would make “Jacqueline du” her given names. The record uses identity.name_parts with given names Jacqueline Mary and the family name “du Pré” (lower-case particle), so the C-CDA and FHIR names are correct; the notes call her Ms. du Pré. Aliases are Jacqueline Mary du Pré and the unaccented Jacqueline du Pre; neither appears in another record. Her family nickname is not used as an alias, because it is part of another figure’s name in this batch.
  4. Death date. 19 October 1987 (Wikipedia, the 2018 review); Women in World History gives 20 October, the date of the New York Times obituary, recorded as a conflicting alternative.
  5. Index age and dates. The synthetic date of birth is 26 January 1998 (shift 53 years). The index visit on 9 March 2026 maps to 9 March 1973, when she was 28: after her last public concerts in London and New York in February 1973 and before the documented diagnosis in London in October 1973. All visits map to March to October 1973, within her lifetime; they are not a claim about where she was. The modern diagnosis comes two weeks after the first visit rather than four years after the first symptoms, which is the intended contrast.
  6. Intake claims. The 1971 loss of sensation and fatigue (CLM-0005), the teen-age visual episodes (CLM-0006, R) and the last concerts (CLM-0007) appear in the intake documents; the diagnosis (CLM-0008), the course (CLM-0010, R) and later events are linked to later timeline events.
  7. Presenting problem. Numbness and clumsiness of the hands with Lhermitte’s sign (R20.2) is resolved at the diagnosis visit on 23 March 2026, when relapsing-remitting multiple sclerosis (G35.A, both_with_link) and vitamin D deficiency (E55.9) are recorded. G35.A is the FY2026 ICD-10-CM code for relapsing-remitting MS. The intake documents state only what was known then.
  8. Earlier episode. The synthetic history of a month of finger tingling 18 months before the first visit is anchored to her documented loss of sensation in her fingers in 1971. The teen-age blurred vision noted by the Mayo authors (CLM-0006) is R and is not used in the modern history; nor is the account of a thigh numbness after anesthesia, which rests on her husband’s recollection.
  9. Diagnostic choices. Aquaporin-4 antibody was tested because the presentation is a myelitis; MOG antibody was not, because nothing in the picture suggests MOG antibody disease. The 2024 McDonald revision was published (Lancet Neurology, September 2025) and is cited alongside the 2017 criteria; she meets both.
  10. Disease-modifying therapy. Ocrelizumab was chosen as early high-efficacy therapy for active disease: natalizumab was set aside because her JCV antibody is positive (index 1.4), and ofatumumab, equally reasonable, was declined at her preference for twice-yearly infusions given her travel. This is a teaching choice for review.
  11. Relapse treatment. Intravenous methylprednisolone 1 g daily for 3 days was used; NICE NG220 prefers oral methylprednisolone 500 mg daily for 5 days, which the consultant names as an equivalent alternative. This is a judgment call for review.
  12. Vaccination timing. PCV20, the first recombinant zoster dose and the first hepatitis B dose were given three weeks before the first infusion; the second hepatitis B dose came two weeks after B-cell depletion began and the second zoster dose three months later. Starting treatment promptly for active disease was judged more important than completing every series first; the resulting non-protective hepatitis B antibody (6 mIU/mL) is recorded and a booster deferred while B cells are depleted.
  13. Synthetic clinical picture. All visits, results, imaging, CSF findings, the JCV, hepatitis B and varicella results, nine-hole peg times (coded as NIH Toolbox nine-hole pegboard times, in seconds), EDSS scores, treatments, her height (173 cm) and weights are synthetic. Qualitative results (CSF, antibodies, serology, pregnancy and urine tests) are in note text only.
  14. Sick visit. Acute uncomplicated cystitis (N30.00) with a pseudo-relapse, seven weeks after the first ocrelizumab course, chosen because infections are more common on anti-CD20 therapy and because telling a pseudo-relapse from a relapse (and not giving steroids for it) is a core teaching point; it insinuates no undocumented real diagnosis. Treated with nitrofurantoin for 5 days.
  15. Preventive visit. A periodic adult preventive visit at 28 (CPT 99395 and 99497 in plain text): inactivated influenza and COVID-19 vaccines, live vaccines avoided on ocrelizumab, cervical screening up to date, chlamydia and gonorrhea screening not indicated over 24 without risk, contraception counseling with an IUD or implant offered, and advance care planning with an unnamed agent.
  16. Focused visits. The four chronic-care follow-ups (diagnosis and consultation, second half-dose, three months with re-baseline MRI, and six months with the first 600 mg dose) are documented as focused visits on the AAN 2018 and ECTRIMS/EAN 2018 guidelines, NICE NG220, the McDonald criteria, the 2021 MAGNIMS-CMSC-NAIMS MRI recommendations and the AAN 2019 vaccination guideline. No new diagnosis is introduced at these visits. One protocol deviation is recorded instead of an invented result: the hepatitis B surface antibody due one to two months after the second vaccine dose was not ordered; recorded at three months; no harm expected; drawn at six months (6 mIU/mL, not protective); corrective action: post-vaccination serology added to the clinic’s B-cell therapy checklist.
  17. Consultation. The neurology referral and the consultation by Rafael Lindgren-Achebe, MD (a fictional consultant), on the diagnosis day, are S. The consultant answers the five referral questions in line with what the record shows afterwards: relapsing-remitting MS by the 2017 and 2024 criteria with mimics excluded; intravenous methylprednisolone for the relapse; ocrelizumab, with the reasons against natalizumab and ofatumumab; screening and vaccinations before B-cell therapy, a re-baseline MRI and blood tests before infusions; occupational therapy and fatigue management; vitamin D; and pregnancy planning.
  18. Music and work. The modern plan has her return to practice, chamber performance and master classes. Her documented history is that the diagnosis ended her performing and that she taught afterwards; the modern course is a teaching contrast, not a claim about what she could have done.
  19. Real people. No relative, friend, colleague or historical physician is named or given a role in the modern episode. Her teachers (William Pleeth, Pablo Casals) and the conductor of her 1965 recording appear only in documented history. No other figure with a record in the dataset is named.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-07-13
Progress note 05 (C-CDA)
Hepatitis B surface antibody after vaccinationOne to two months after the last dose, for people on immunosuppressive therapyMissed: the antibody check due one to two months after the second hepatitis B dose was not ordered. No harm is expected in the meantime, since she has no hepatitis B exposure; corrective action: added to the blood tests before the next ocrelizumab dose, and post-vaccination serology added to the clinic's B-cell therapy checklist

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-03-23
Progress note 02 (C-CDA)
ReferralOccupational therapyReferredAssessment booked for next week

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0006Two physicians writing about her illness note episodes of blurred vision in her teens, which they read as possibly an early sign of multiple sclerosis.possible
CLM-0010Corticosteroids were the treatment available to her; physicians writing later judge that her illness followed a relapsing-remitting course that became secondary progressive.probable

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-03-2325-hydroxyvitamin D16 ng/mL (low)Low
2026-06-15C-reactive protein14 mg/L (high)High
2026-07-13CD19 B cells3 /uL (low)Low
2026-10-12Hepatitis B surface antibody6 m[IU]/mL (low)Low